Optimi Health Announces Leadership Transition
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, has announced a leadership transition. Mr. William (Bill) Ciprick is stepping down as Chief Executive Officer due to personal reasons after three years of leading the company.
The Board of Directors has appointed Mr. Dane Stevens, Co-Founder of Optimi, as Interim Chief Executive Officer, effective immediately. Mr. Stevens will focus on advancing key initiatives, including business development, expanding revenue opportunities, and maintaining the company's strategic direction. Mr. Ciprick will continue to support the company in an advisory capacity during this transition period.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), un produttore di psichedelici conforme GMP e autorizzato da Health Canada specializzato in psilocibina botanica e MDMA, ha annunciato una transizione alla leadership. Il signor William (Bill) Ciprick si dimette dalla carica di Amministratore Delegato per motivi personali dopo tre anni di guida dell'azienda.
Il Consiglio di Amministrazione ha nominato il signor Dane Stevens, cofondatore di Optimi, come Amministratore Delegato ad interim, con effetto immediato. Il signor Stevens si concentrerà sullo sviluppo di iniziative chiave, inclusi sviluppo aziendale, espansione delle opportunità di reddito e mantenimento della direzione strategica dell'azienda. Il signor Ciprick continuerà a supportare l'azienda in qualità di consulente durante questo periodo di transizione.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), un fabricante de psicodélicos cumpliendo con GMP y autorizado por Health Canada especializado en psilocibina botánica y MDMA, ha anunciado una transición en el liderazgo. El Sr. William (Bill) Ciprick deja su cargo como Director Ejecutivo por razones personales después de tres años al frente de la empresa.
La Junta Directiva ha nombrado al Sr. Dane Stevens, cofundador de Optimi, como Director Ejecutivo interino, con efecto inmediato. El Sr. Stevens se enfocará en avanzar en iniciativas clave, incluyendo desarrollo empresarial, expansión de oportunidades de ingresos y mantenimiento de la dirección estratégica de la empresa. El Sr. Ciprick seguirá apoyando a la empresa en calidad de asesor durante este período de transición.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN)은 GMP 규정을 준수하고 Health Canada의 승인을 받은 정신약물 제조업체로, 식물성 실로시빈 및 MDMA를 전문으로 하며, 리더십 전환을 발표했습니다. William (Bill) Ciprick 씨가 CEO 직에서 물러납니다 개인적인 사유로 3년간 회사를 이끌어온 후입니다.
이사회는 Optimi의 공동 창립자인 Dane Stevens 씨를 임시 CEO로 임명했습니다, 즉시 발효됩니다. Stevens 씨는 사업 개발, 수익 기회 확장, 회사의 전략적 방향 유지 등 주요 이니셔티브를 진행하는 데 집중할 것입니다. Ciprick 씨는 이 전환 기간 동안 회사에 자문 역할로 계속 지원할 예정입니다.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), un fabricant de psychédéliques conforme aux normes GMP et licencié par Health Canada, spécialisé dans la psilocybine botanique et la MDMA, a annoncé une transition de direction. M. William (Bill) Ciprick démissionne de son poste de Directeur Général pour des raisons personnelles après trois ans à la tête de l'entreprise.
Le Conseil d'Administration a nommé M. Dane Stevens, co-fondateur d'Optimi, en tant que Directeur Général par intérim, avec effet immédiat. M. Stevens se concentrera sur la promotion d'initiatives clés, y compris le développement commercial, l'expansion des opportunités de revenus et le maintien de l'orientation stratégique de l'entreprise. M. Ciprick continuera à soutenir l'entreprise en tant que conseiller pendant cette période de transition.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), ein GMP-konformer, von Health Canada lizenzierter Hersteller von Psychedelika, der sich auf botanische Psilocybin und MDMA spezialisiert hat, hat einen Führungswechsel angekündigt. Herr William (Bill) Ciprick tritt aus persönlichen Gründen als CEO zurück, nachdem er drei Jahre lang das Unternehmen geleitet hat.
Der Vorstand hat Herrn Dane Stevens, Mitbegründer von Optimi, als Interim-CEO ernannt, mit sofortiger Wirkung. Herr Stevens wird sich darauf konzentrieren, wichtige Initiativen voranzutreiben, einschließlich Geschäftsentwicklung, Erweiterung von Einnahmequellen und Erhaltung der strategischen Ausrichtung des Unternehmens. Herr Ciprick wird das Unternehmen während dieser Übergangszeit in beratender Funktion weiterhin unterstützen.
- Appointment of Co-Founder Dane Stevens as Interim CEO ensures continuity in leadership
- Focus on business development and expanding revenue opportunities
- Unexpected departure of CEO William Ciprick may cause short-term uncertainty
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons.
"During his three years of leadership, Bill has played a key role in bringing Optimi's GMP psychedelics to market and to patients in Australia," said Optimi Co-Founder and Chair of the Board, JJ Wilson. "The Board of Directors extends its deepest gratitude for his dedication and leadership, which have been instrumental in establishing the Company's industry presence. We are pleased that Bill will continue to support the Company in an advisory capacity throughout this transition."
Effective immediately, the Board has appointed Mr. Dane Stevens, Co-Founder of Optimi, as Interim Chief Executive Officer. In this role, Mr. Stevens will continue to advance the Company's key initiatives, with a focus on business development, expanding revenue opportunities, and maintaining the Company's strategic direction.
About Optimi Health Corp.
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading psychedelics pharmaceutical manufacturer licensed by Health Canada. Specializing in controlled substances such as botanical psilocybin and MDMA, Optimi is dedicated to supplying safe, GMP-grade products and APIs to researchers, drug developers, and authorized patients worldwide. Optimi's facilities in Princeton, British Columbia, are designed for the development of proprietary formulations under strict GACP and GMP standards, ensuring unparalleled quality and reliability. The Company is committed to being the most trusted supplier of safe psychedelic drug candidates globally.
On behalf of the Board of Directors,
OPTIMI HEALTH CORP.
JJ Wilson, Chair of the Board
For more information, please contact the Company at:
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-Looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227241
FAQ
Why is William Ciprick stepping down as CEO of Optimi Health (OPTHF)?
Who has been appointed as the Interim CEO of Optimi Health (OPTHF)?
What will be the focus of the new Interim CEO of Optimi Health (OPTHF)?
Will William Ciprick continue to be involved with Optimi Health (OPTHF) after stepping down as CEO?
